Yahoo! FinanceHome - Yahoo! - Help

Market Guide

[ Stock Screener | Company & Fund Index | Financial Glossary ]

Profile - Antigenics, Inc. (NasdaqNM:AGEN)
As of 31-Aug-2001
Enter symbol:
symbol lookup

 
More Info: Quote | Chart | News | Profile | Research | SEC | Msgs | Insider | Financials
Location
630 Fifth Street, Suite 2100
New York, NY 10111
Phone: (212) 332-4774
Fax: (212) 332-4778
Email: ir@antigenics.com
Employees (last reported count): 162
Financial Links
 ·Top Institutional Holders
 ·Top Mutual Fund Holders
 ·Analyst Upgrade/Downgrade History
 ·Historical Quote Data
 ·Raw SEC Filings at sec.gov
Competitors:
 ·Sector: Healthcare
 ·Industry: Biotechnology & Drugs
Company Websites
 ·Home Page
 ·Investor Relations
 ·Yahoo! Category

 ·Search Yahoo! for related links...

Ownership
·Insider and 5%+ Owners: 49%
·Over the last 6 months:
 · 3 insider buys; 21.0K shares (0.1% of insider shares)
·Institutional: 20% (38% of float)
(89 institutions)
·Net Inst. Buying: 491.0K shares (+7.98%)
(prior quarter to latest quarter)
More From Market Guide
 ·Highlights
 ·Performance
 ·Ratio Comparisons
Business Summary
Antigenics, Inc. is developing treatments for cancers, serious infectious diseases, autoimmune disorders and degenerative disorders, using the Company's proprietary technologies to program the immune system and improve quality of life. These products include immunotherapeutics based on a specific class of heat shock proteins (HSPs), which activate powerful cellular immune responses, and Stimulon-based products, including QS-21, which activates superior antibody responses. At year-end 2000, the Company was evaluating its lead HSP-based immunotherapeutic, Oncophage, in an international multi-center Phase III clinical trial in kidney cancer, and in five additional cancer indications in Phase II or Phase I/II trials. Through its internal programs and partnerships, the Company was also testing its Stimulon-based products in 11 Phase III and Phase II clinical trials for cancer, several infectious diseases and degenerative disorders.
More from Market Guide: Expanded Business Description

Financial Summary
Antigenics, Inc. is engaged in the discovery and development of novel immunotherapeutic drugs for the treatment of life threatening and chronic medical conditions. For the six months ended 6/30/01, revenues totalled $2.2 million, up from $0. Net loss rose 71% to $15.7 million. Revenues reflect product sales attributable to the acquisition of Aquila Pharmaceuticals. Higher loss reflects increased personnel, R&D and administrative expenses.
More from Market Guide: Significant Developments

Officers[Insider Trade Data]
FY2000 Pay

Garo Armen, Ph.D., 48
Chairman, CEO
$500K
Elma Hawkins, Ph.D., 44
Vice Chairman
252K
Gamil De Chadarevian, 49
Vice Chairman, Exec. VP International
--  
Russell Herndon, 42
COO
--  
Neal Gordon, Ph.D., 38
VP of Operations
176K
Dollar amounts are as of 31-Dec-2000 and compensation values are for the fiscal year ending on that date; "Pay" is salary, bonuses, etc..
More from Market Guide on Officers & Directors:
Expanded List, Bios, Compensation, Options
Statistics at a Glance -- NasdaqNM:AGENAs of 31-Aug-2001
Price and Volume
52-Week Low
on 29-Dec-2000
$10.25 
Recent Price$15.99 
52-Week High
on 12-June-2001
$21.38 
Daily Volume (3-month avg)97.6K
Daily Volume (10-day avg)56.0K
Stock Performance
[one-year price graph]
big chart [1d | 5d | 3m | 6m | 1y | 2y]
52-Week Change-12.1%
52-Week Change
relative to S&P500
+17.9%
Share-Related Items
Market Capitalization$463.5M
Shares Outstanding29.0M
Float14.8M
Dividends & Splits
Annual Dividendnone 
Last Splitnone 
Per-Share Data
Book Value (mrq)$3.74 
Earnings (ttm)-$2.02 
Earnings (mrq)-$0.31 
Sales (ttm)$0.10 
Cash (mrq)$2.98 
Valuation Ratios
Price/Book (mrq)4.28 
Price/EarningsN/A 
Price/Sales (ttm)162.09 
Income Statements
Sales (ttm)$2.60M
EBITDA (ttm)-$57.9M
Income available to common (ttm)-$53.3M
Profitability
Profit MarginN/A 
Operating MarginN/A 
Fiscal Year
Fiscal Year EndsDec 31
Most recent quarter30-June-2001
Management Effectiveness
Return on Assets (ttm)-45.41%
Return on Equity (ttm)-48.69%
Financial Strength
Current Ratio (mrq)11.02 
Debt/Equity (mrq)0.04 
Total Cash (mrq)$81.6M
Short Interest
As of 8-Aug-2001
Shares Short1.52M
Percent of Float10.3%
Shares Short
(Prior Month)
1.34M
Short Ratio11.41 
Daily Volume133.0K
See Profile Help for a description of each item above;   K = thousands;   M = millions;   mrq = most-recent quarter;   ttm = trailing twelve months;   (as of 30-June-2001)

Market Guide offers more in-depth Company Research, Stock Screening, and Hottest Stocks and Industries on over 10,000 U.S. Equities.


Copyright © 2001 Yahoo! Inc. All Rights Reserved. Privacy Policy - Terms of Service
Company information Copyright Market Guide. Historical chart data and daily updates provided by Commodity Systems, Inc. (CSI). Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither Yahoo nor any of its data or content providers (such as Market Guide, CSI, etc.) shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon.